• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $LUNA

    Luna Innovations Incorporated

    Subscribe to $LUNA
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations Incorporated develops, manufactures, and markets fiber optic test, measurement, and control products worldwide. It operates through two segments, Lightwave and Luna Labs. The Lightwave segment offers test and measurement products, which include optical vector analyzer, optical backscatter reflectometers, and the Phoenix family of tunable lasers; and Hyperion sensing solution that enable full-spectrum data acquisition and flexible peak detect algorithms of fiber-bragg grating (FBG), long period FBGs and fabry-perot sensors with low-latency access to data for closed loop feedback applications. This segment also provides polarization control products, including components, modules, and instruments to measure, manage, and control polarization and group delay in fiber optic networks; tunable lasers; Terametrix terahertz gauging and imaging products that provides precise single and multi-layer thickness, density, basis weight, and caliper thickness measurements; ODiSI sensing solution, which provides distributed strain and temperature measurements; and Hyperion sensing products that targets fiber optic sensing applications. The Luna Labs segment provides applied research for customers principally in the areas of sensing and materials, such as coatings, adhesives, composites, and bio-engineered materials. The company sells its products to telecommunications companies, defense agencies, government system integrators, researchers, original equipment manufacturers, distributors, testing labs, and strategic partners directly, as well as through manufacturer representative organizations, partner and distribution channels, technical sales engineers, value added resellers, and independent sales representatives. Luna Innovations Incorporated was incorporated in 1990 and is headquartered in Roanoke, Virginia.

    IPO Year: 2006

    Exchange: NASDAQ

    Website: lunainc.com

    Recent Analyst Ratings for Luna Innovations Incorporated

    DatePrice TargetRatingAnalyst
    7/28/2023$12.50Buy
    Stifel
    5/22/2023$10.00Buy
    Needham
    3/15/2023$8.00Outperform → Market Perform
    Northland Capital
    5/23/2022$8.00Market Perform → Outperform
    Northland Capital
    See more ratings

    Luna Innovations Incorporated Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Luna Innovations Announces Baker Tilly as New Independent Auditor

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

      4/2/25 8:52:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Updates on Operating Metrics and Intent to Deregister Stock

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announces an update on select operating metrics. The Company is also communicating its intent to voluntarily accelerate its delisting from Nasdaq and ultimately deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including suspending its reporting obligations under Section 15(d) of the Exchange Act. The accelerated delisting and deregistration process will not adversely affect Luna's ongoing operations or the listing of the Company's common stock on the OTC Experts Market. "Luna star

      1/27/25 10:24:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Stock to Be Suspended from Nasdaq Listing

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, due to the Company's inability to meet the March 27, 2025 deadline to file its previously disclosed delinquent filings with the Securities and Exchange Commission to regain compliance, the trading in its securities will be suspended tomorrow, January 7, 2025, and subsequently delisted from The Nasdaq Stock Market LLC ("Nasdaq"). Following the suspension, the Company expects its shares to be eligible to trade on the over-the-counter ("OTC") market, specifically the OTC Expert Market. The suspension/delisting of the Company's stock from Nasdaq does not

      1/6/25 8:30:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Resignation of Pamela Coe

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, Pamela Coe, a member of the Board of Directors (the "Board"), will be retiring from the Luna board effective today. Ms. Coe was elected to the Board in May 2021 for a three-year term. "We are very grateful for Pam's notable contributions and leadership throughout her time on the Board," said Barry Phelps, Chairman of the Board of the Company. "Her expertise, focus and commitment have been instrumental in guiding Luna. We wish Pam all the best in her future endeavors." About Luna Luna Innovations Incorporated (www.lunainc.com) is a leader in optic

      12/27/24 4:40:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Receives Additional Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that it has received a written notice (the "Notice") on November 14, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the quarter ended September 30, 2024 (the "Q3 2024 Form 10-Q") and because the Company remains delinquent in filing its Form 10-Qs for the quarters ended March 31, 2024 (the "Q1 2024 Form 10-Q") and June 30, 2024 (the "Q2 2024 Form 10-Q") and its Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K", and collectively w

      11/15/24 4:50:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Announces CFO Transition: Names William Phelan as Chief Financial Officer and Chief Accounting Officer

      Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the appointment of William L. Phelan as its new Chief Financial Officer and Chief Accounting Officer, effective immediately. Mr. Phelan succeeds John Roiko, who joined Luna out of retirement in May 2024 and played a key role in establishing a resilient foundation for Luna's future growth. Following the appointment of Mr. Phelan, Mr. Roiko will shift to a consulting role to support the ongoing restatement process. "We are delighted to welcome Bill to the Luna leadership team," said Kevin Ilcisin, President and CEO of Luna. "Bill's highly relevant experience will be instrume

      10/16/24 4:30:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Announces Receipt of Nasdaq Staff Determination Letter

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that on October 1, 2024, it received a staff determination letter (the "Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, due to the Company's failure to regain compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"), Nasdaq has determined (the "Determination") that the Company's securities will be scheduled for delisting from Nasdaq

      10/7/24 4:30:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Announces Receipt of Additional Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that it has received a written notice (the "Notice") on August 20, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the quarter ended June 30, 2024 (the "Q2 2024 Form 10-Q") and because the Company remains delinquent in filing its Form 10-Q for the quarter ended March 31, 2024 (the "Q1 2024 Form 10-Q") and its Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule

      8/26/24 5:00:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Appointment of Kevin Ilcisin as CEO, Retirement of Richard Roedel and $15 Million Credit Facility from White Hat Capital Partners

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced the appointment of Kevin Ilcisin as its new President and Chief Executive Officer, the retirement of Richard Roedel from the Board of Directors (the "Board") after nearly 20 years of service, and the closing of a $15 million junior secured term loan facility (the "Loan Facility"). New President and CEO: Effective August 1, 2024, Mr. Ilcisin will assume his new role as the President, CEO and member of the Board of the Company. Mr. Ilcisin has been a strategic advisor to the Company since April 2024, bringing a wealth of experience, industry knowledge and

      7/23/24 5:36:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated investors: Please contact the Portnoy Law Firm to recover your losses; May 31, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Luna Innovations Incorporated (NASDAQ:LUNA) investors that a lawsuit was filed on behalf of investors that purchased Luna securities between May 16, 2022 and April 19, 2024 inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to

      5/28/24 6:25:35 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    Luna Innovations Incorporated Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spiegel Gary converted options into 10,672 shares, increasing direct ownership by 15% to 81,625 units (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      1/3/25 4:44:17 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Anderson N Leigh converted options into 19,869 shares, increasing direct ownership by 122% to 36,102 units (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      1/3/25 4:43:48 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Coe Pamela L converted options into 13,372 units of Common Stock (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      12/26/24 5:52:51 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Chanley David

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      10/29/24 4:05:18 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Chief Financial Officer Phelan William Lawrence was granted 150,000 units of Common Stock (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      10/21/24 5:12:25 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 3 filed by new insider Phelan William Lawrence

      3 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      10/21/24 5:11:28 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Spiegel Gary

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      10/3/24 5:24:34 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Vitale Mary Beth

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      10/3/24 5:24:06 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Phelps Barry

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      10/3/24 5:23:32 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • New insider Ilcisin Kevin claimed ownership of 628,141 units of Common Stock (SEC Form 3)

      3 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      8/12/24 6:08:13 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    Luna Innovations Incorporated Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Luna Innovations with a new price target

      Stifel initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $12.50

      7/28/23 7:35:40 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Needham initiated coverage on Luna Innovations with a new price target

      Needham initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $10.00

      5/22/23 7:57:49 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations downgraded by Northland Capital with a new price target

      Northland Capital downgraded Luna Innovations from Outperform to Market Perform and set a new price target of $8.00

      3/15/23 8:52:49 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations upgraded by Northland Capital with a new price target

      Northland Capital upgraded Luna Innovations from Market Perform to Outperform and set a new price target of $8.00

      5/23/22 9:08:48 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • B. Riley resumed coverage on Luna Innovations with a new price target

      B. Riley resumed coverage of Luna Innovations with a rating of Buy and set a new price target of $14.50 from $12.50 previously

      3/12/21 8:13:37 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    Luna Innovations Incorporated Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/14/24 12:32:28 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/14/24 8:39:20 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Luna Innovations Incorporated

      SC 13G/A - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/12/24 4:02:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Luna Innovations Incorporated

      SC 13G/A - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/4/24 3:14:45 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Luna Innovations Incorporated

      SC 13G/A - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/4/24 1:43:24 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Luna Innovations Incorporated

      SC 13D/A - LUNA INNOVATIONS INC (0001239819) (Subject)

      10/29/24 4:10:15 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      10/15/24 2:51:26 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Luna Innovations Incorporated

      SC 13D/A - LUNA INNOVATIONS INC (0001239819) (Subject)

      7/23/24 5:30:16 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      2/13/24 5:08:13 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Luna Innovations Incorporated (Amendment)

      SC 13G/A - LUNA INNOVATIONS INC (0001239819) (Subject)

      1/30/24 4:49:38 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    Luna Innovations Incorporated Leadership Updates

    Live Leadership Updates

    See more
    • Luna Innovations Announces Baker Tilly as New Independent Auditor

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

      4/2/25 8:52:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Resignation of Pamela Coe

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, Pamela Coe, a member of the Board of Directors (the "Board"), will be retiring from the Luna board effective today. Ms. Coe was elected to the Board in May 2021 for a three-year term. "We are very grateful for Pam's notable contributions and leadership throughout her time on the Board," said Barry Phelps, Chairman of the Board of the Company. "Her expertise, focus and commitment have been instrumental in guiding Luna. We wish Pam all the best in her future endeavors." About Luna Luna Innovations Incorporated (www.lunainc.com) is a leader in optic

      12/27/24 4:40:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Announces CFO Transition: Names William Phelan as Chief Financial Officer and Chief Accounting Officer

      Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the appointment of William L. Phelan as its new Chief Financial Officer and Chief Accounting Officer, effective immediately. Mr. Phelan succeeds John Roiko, who joined Luna out of retirement in May 2024 and played a key role in establishing a resilient foundation for Luna's future growth. Following the appointment of Mr. Phelan, Mr. Roiko will shift to a consulting role to support the ongoing restatement process. "We are delighted to welcome Bill to the Luna leadership team," said Kevin Ilcisin, President and CEO of Luna. "Bill's highly relevant experience will be instrume

      10/16/24 4:30:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Appointment of Kevin Ilcisin as CEO, Retirement of Richard Roedel and $15 Million Credit Facility from White Hat Capital Partners

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced the appointment of Kevin Ilcisin as its new President and Chief Executive Officer, the retirement of Richard Roedel from the Board of Directors (the "Board") after nearly 20 years of service, and the closing of a $15 million junior secured term loan facility (the "Loan Facility"). New President and CEO: Effective August 1, 2024, Mr. Ilcisin will assume his new role as the President, CEO and member of the Board of the Company. Mr. Ilcisin has been a strategic advisor to the Company since April 2024, bringing a wealth of experience, industry knowledge and

      7/23/24 5:36:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated investors: Please contact the Portnoy Law Firm to recover your losses; May 31, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Luna Innovations Incorporated (NASDAQ:LUNA) investors that a lawsuit was filed on behalf of investors that purchased Luna securities between May 16, 2022 and April 19, 2024 inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to

      5/28/24 6:25:35 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated investors: Please contact the Portnoy Law Firm to recover your losses; May 31, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 21, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Luna Innovations Incorporated (NASDAQ:LUNA) investors that a lawsuit was filed on behalf of investors that purchased Luna securities between August 11, 2023 and March 25, 2024 inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to

      5/21/24 3:58:31 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated investors: Please contact the Portnoy Law Firm to recover your losses; May 31, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Luna Innovations Incorporated (NASDAQ:LUNA) investors that a lawsuit was filed on behalf of investors that purchased Luna securities between August 11, 2023 and March 25, 2024 inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims t

      5/13/24 7:20:45 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated investors: Please contact the Portnoy Law Firm to recover your losses; May 31, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Luna Innovations Incorporated (NASDAQ:LUNA) investors that a lawsuit was filed on behalf of investors that purchased Luna securities between August 11, 2023 and March 25, 2024 inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claim

      5/9/24 10:01:29 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Appoints New Senior Leadership Across Sales and Product Marketing

      Will Denman Joins Luna as Senior Vice President, Sales, North America Matthew Friedman Recently Appointed Vice President, Product Marketing Heather Matzke-Hamlin Joins Luna as Public Accounting Advisor Luna Innovations Incorporated (NASDAQ:LUNA) ("Luna" or the "Company"), a global leader in advanced fiber optic-based technology, today announced the appointment of two new members of its senior leadership team. Will Denman is appointed Senior Vice President, Sales, North America, overseeing the company's customer success and sales operations and strategy, effective May 1, 2024. Prior to joining Luna, Mr. Denman served as Senior Vice President of Global Sales and Marketing for Nationa

      5/2/24 9:20:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated investors: Please contact the Portnoy Law Firm to recover your losses; May 31, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 02, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Luna Innovations Incorporated (NASDAQ:LUNA) investors that a lawsuit was filed on behalf of investors that purchased Luna securities between August 11, 2023 and March 25, 2024 inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing

      4/2/24 3:26:46 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    Luna Innovations Incorporated Financials

    Live finance-specific insights

    See more
    • Luna Innovations to Delay Release of Fourth Quarter and Full Year 2023 Financial Results

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced it will delay the release of its fourth quarter and fiscal year 2023 financial results and the subsequent conference call. A Special Committee of the Company's Board of Directors is conducting an independent review, with the assistance of external legal and financial advisors, of certain transactions for which revenue was recognized in the second and third quarters of 2023 that did not qualify for revenue recognition under U.S. generally accepted accounting principles. The Special Committee is examining the circumstances surrounding these issues and is eva

      3/12/24 4:20:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces $50 Million Strategic Investment from White Hat Capital Partners

      Investment Proceeds Used to Fund Silixa Acquisition and Enhance Luna's Financial Flexibility to Pursue Strategic Growth Initiatives Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced a $50 million investment by White Hat Capital Partners ("White Hat"), an investment firm focused on sustainable value creation in technology companies serving mission-critical applications. Proceeds from this strategic investment were partially used to fund the acquisition of Silixa, also announced today, and related transaction costs in the aggregate amount of approximately $25 million. Remaining proceeds were used to repay the Company's o

      12/21/23 9:34:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Acquires Silixa

      Strengthens Portfolio of Distributed Fiber Optic Sensing Solutions Adds Significant New Growth Markets and Applications and Further Expands Global Footprint Conference Call Scheduled for Today, December 21st, at 11:00 AM ET Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the strategic acquisition of Silixa, a UK-based leader in distributed fiber optic sensing solutions. The acquisition further propels Luna's position in the fiber optic sensing market, adding capabilities in distributed acoustic sensing (DAS), distributed temperature sensing (DTS) and distributed strain sensing (DSS) that offer enhanced performance

      12/21/23 9:32:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Reports Third Quarter 2023 Results

      Q3 Highlights Total revenue of $30.7 million, up 5% year over year Gross margin of 57%, compared to 58% for the prior year Net income of $0.5 million, compared to net income of $1.2 million for the prior year Adjusted EBITDA of $4.2 million, compared to $4.5 million for the prior year Adjusted EPS of $0.07, compared to $0.09 for the prior year Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced optical technology, today announced its financial results for the three and nine months ended September 30, 2023. "We delivered solid performance this quarter in spite of continued macroeconomic headwinds," said Scott Graeff, President and Chief Executive Offi

      11/14/23 7:30:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Third-Quarter 2023 Financial Release Date of November 14, 2023

      Roanoke, VA, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Luna Innovations Incorporated (NASDAQ:LUNA) announced today it will report its third-quarter financial results for the period ended September 30, 2023, before the open of the stock market on Tuesday, November 14, 2023.  Following the release, Scott Graeff, President and Chief Executive Officer; George Gomez-Quintero, Chief Financial Officer; and Brian Soller, Chief Technology Officer will host a conference call at 8:30 a.m. Eastern to discuss the third-quarter 2023 earnings results. The investor conference call will be available via live webcast on the Luna website at www.lunainc.com under the tab "Investor Relations." To participate by tele

      11/3/23 3:30:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Reports Second-Quarter 2023 Results

      Reaffirms Full-Year 2023 Outlook Q2 Highlights Total revenues of $29.2 million, up 11% year over year Gross margin of 58%, compared to 61% for the prior year Net loss of $1.6 million, compared to net loss of $2.4 million for the prior year Adjusted EBITDA of $2.7 million, compared to $1.2 million for the prior year Adjusted EPS of $0.04, compared to $(0.02) for the prior year Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced optical technology, today announced its financial results for the three and six months ended June 30, 2023. "We continue to see abundant opportunities for Luna's capabilities and are particularly pleased this quarter with str

      8/10/23 4:05:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Second-Quarter 2023 Financial Release Date of August 10, 2023

      Roanoke, VA, July 31, 2023 (GLOBE NEWSWIRE) -- Luna Innovations Incorporated (NASDAQ:LUNA) announced today it will report its second-quarter financial results for the period ended June 30, 2023, at the close of the stock market on Thursday, August 10, 2023. Following the release, Scott Graeff, President and Chief Executive Officer; Gene Nestro, Chief Financial Officer; and Brian Soller, Chief Technology Officer will host a conference call at 5:00 p.m. Eastern to discuss the second-quarter 2023 earnings results. The investor conference call will be available via live webcast on the Luna website at www.lunainc.com under the tab "Investor Relations." To participate by telephone, the domestic

      7/31/23 4:00:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Reports Strong First-Quarter 2023 Results

      Reaffirms Full-Year 2023 Outlook Q1 Highlights Total revenues of $25.0 million, up 11% year over year Total revenues in constant currency of $25.3 million; up 13% year-over-year Gross margin of 60%, compared to 64% for the prior year Net loss of $1.8 million, compared to net income of $9.6 million for the prior year, which included the gain on sale of Luna Labs Adjusted EBITDA of $0.9 million, compared to $1.7 million for the prior year Adjusted EPS of $0.00, compared to $0.05 for the prior year Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced optical technology, today announced its financial results for the three months ended March 31, 2023.

      5/9/23 7:00:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces First-Quarter 2023 Financial Release Date of May 9, 2023

      Roanoke, VA, April 28, 2023 (GLOBE NEWSWIRE) -- Luna Innovations Incorporated (NASDAQ:LUNA) announced today it will report its first-quarter financial results for the period ended March 31, 2023, before the open of the stock market on Tuesday, May 9, 2023. Following the release, Scott Graeff, President and Chief Executive Officer; Gene Nestro, Chief Financial Officer; and Brian Soller, Chief Technology Officer will host a conference call at 8:00 a.m. Eastern to discuss the first-quarter 2023 earnings results. The investor conference call will be available via live webcast on the Luna website at www.lunainc.com under the tab "Investor Relations." To participate by telephone, the dome

      4/28/23 8:30:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Reports Strong Fourth-Quarter and Full-Year 2022 Results

      Provides 2023 Guidance Q4 Financial Highlights Revenues of $31.7 million, up 31% year over year Revenues in constant currency of $32.5 million; up 34% year over year Gross margin of 61%, compared to 58% for the prior year Net income of $0.9 million, compared to net income of $1.6 million for the prior year Adjusted EBITDA of $4.7 million, compared to $3.1 million for the prior year Adjusted EPS of $0.08, compared to $0.08 for the prior year Full-Year Financial Highlights Revenues of $109.5 million, up 25% year over year Revenues in constant currency of $111.9 million; up 28% year over year Gross margin of 61%, compared to 59% for the prior year Net income of $9.3

      3/14/23 4:05:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    Luna Innovations Incorporated SEC Filings

    See more
    • Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/27/25 10:26:44 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated

      SCHEDULE 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      1/14/25 1:56:29 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/6/25 8:30:40 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      12/27/24 4:40:48 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form NT 10-Q filed by Luna Innovations Incorporated

      NT 10-Q - LUNA INNOVATIONS INC (0001239819) (Filer)

      11/15/24 4:54:16 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      11/15/24 4:53:25 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      10/29/24 9:21:59 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      10/16/24 4:37:09 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      10/7/24 4:38:05 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      8/26/24 5:08:09 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care